Literature DB >> 10383562

Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

B Vadher1, D L Patterson, M Leaning.   

Abstract

AIMS: A pharmacokinetic/pharmacodynamic model, with Bayesian parameter estimation, was used to retrospectively predict the daily International Normalized Ratios (INRs) and the maintenance doses during the initiation of warfarin therapy in 74 inpatients.
METHODS: INRs and maintenance doses predicted by the model were compared with the actual INRs and the eventual maintenance dose. Cases with drugs or medical conditions interacting with warfarin or receiving concurrent heparin therapy were not excluded. As the study was retrospective, model predictions of the maintenance dose were not those that were administered. Mean prediction error (MPE) and percentage absolute prediction errors (PAPE) were used to assess the model predictions.
RESULTS: INR MPE ranged from -0.07 to 0.06 and median PAPE from 10% to 20%. Dose MPE ranged from -0.7 to 0.17 mg and median PAPE from 16.7% to 37.5%. Accurate and precise dose predictions were obtained after 3 or more INR feedback's.
CONCLUSIONS: This study shows that the model can accurately predict daily INRs and the maintenance dose in this sample of cases. The model can be incorporated into computer decision-support systems for warfarin therapy and may lead to improvement in the initiation of warfarin therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383562      PMCID: PMC2014877          DOI: 10.1046/j.1365-2125.1999.00967.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  THE EFFECT OF THE USE OF DIFFERENT TISSUE EXTRACTS ON ONE-STAGE PROTHROMBIN TIMES.

Authors:  L POLLER
Journal:  Acta Haematol       Date:  1964-11       Impact factor: 2.195

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

4.  One-stage prothrombin time survey.

Authors:  S Zucker; E Brosious; G R Cooper
Journal:  Am J Clin Pathol       Date:  1970-03       Impact factor: 2.493

5.  International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control.

Authors: 
Journal:  Thromb Haemost       Date:  1985-02-18       Impact factor: 5.249

6.  Flexible induction dose regimen for warfarin and prediction of maintenance dose.

Authors:  A Fennerty; J Dolben; P Thomas; G Backhouse; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

Review 7.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

8.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

9.  Pharmacokinetics and pharmacodynamics of warfarin at steady state.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

10.  Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations.

Authors:  Y Stirling; D J Howarth; R Stockley; R Bland; C M Towler; S M Harding
Journal:  Br J Haematol       Date:  1982-05       Impact factor: 6.998

View more
  3 in total

1.  Development of a bayesian forecasting method for warfarin dose individualization.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Pharm Res       Date:  2011-02-08       Impact factor: 4.200

2.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

3.  Beyond warfarin: The advent of new oral anticoagulants.

Authors:  Sandeep T Laroia; Steven Morales; Archana T Laroia
Journal:  Indian J Radiol Imaging       Date:  2015 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.